Celgene Careers NewsEmployer Directory Featured Listing, Feeds and Subscriptions

The latest Celgene careers news and job posts. Subscribe for daily updates to your inbox, mobile device and/or smartphone.

  Jobs Feed | Subscribe  

Description Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of hum...
Posted: February 16, 2019, 7:03 pm
Description Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of hum...
Posted: February 16, 2019, 7:03 pm
Description Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of hum...
Posted: February 16, 2019, 7:03 pm
Description Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of hum...
Posted: February 16, 2019, 7:03 pm
Description Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of hum...
Posted: February 16, 2019, 7:03 pm

Viewing page 1 of 99|Next Page

  Newsfeed | Subscribe  

Researchmoz added Most up-to-date research on "Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline" to ...
Posted: February 18, 2019, 3:54 am
If there was a "Bad News Bears" team of biotechs, Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD) would probably be the star players. Both Celgene and Gilead have experienced more than their f...
Posted: February 17, 2019, 6:00 am
(Reuters) - Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker’s $74 billion deal to bu...
Posted: February 15, 2019, 6:10 pm
Bristol-Myers Squibb (BMY) is spending $74 billion in its Celgene acquisition, but an analyst said Friday that the drugmaker could, itself, be a potential takeover target. Nearly 87% of respondents in ...
Posted: February 15, 2019, 10:25 am
When Gilead Sciences (NASDAQ:GILD) reported earnings earlier this month, shares stagnated a bit but stayed above the 50-day moving average. That gave investors a reasonable level to measure against.
Posted: February 13, 2019, 1:59 pm

Viewing page 1 of 3|Next Page